MIGS has triggered a shift in the glaucoma paradigm, enabling surgical intervention that bridges the gap between medical management and invasive surgery. While much of the focus has been on stent-based procedures, DR NATHAN KERR says surgeons should be excited by an entirely different approach by Australia’s Nova Eye Medical.
The first corneal allogenic intrastromal ring segment (CAIRS) surgery in Australia has been performed at the Queensland Eye Institute (QEI), paving the way to better sight for keratoconus patients.
A new paper comparing axial elongation differences among untreated myopes, myopes fitted with a control contact lens and emmetropes has helped further the understanding of myopia control efficacy in the context of normal childhood eye growth. Read more
Glaukos has secured Australian regulatory approval for the Preserflo MicroShunt, offering late-stage glaucoma patients a more elegant surgical alternative to conventional filtration procedures. Read more
Eight Australian researchers are taking their projects to the next level with a share of more than $1 million in research funding from Macular Disease Foundation Australia (MDFA). Read more
As part of Macula Month this May, Insight examines drug development programs that could significantly alter the late-stage AMD therapy landscape. Leading experts also discuss why optometrists are such an important link in the success of both patient outcomes and clinical trials.
Australia’s first clinical trials of an investigational gene therapy for dry age-related macular degeneration (AMD) has commenced at the Centre for Eye Research Australia (CERA). Read more
The Therapeutic Goods Administration (TGA) has confirmed a shortage of Prednefrin Forte 10mL eye drops in Australia, which isn’t expected to be available until January next year, but its supplier has confirmed it is working towards providing an alternative product. Read more
An independent expert panel has recommended Novartis’ treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related macular degeneration (nAMD) patients as a second-line anti-VEGF treatment. Read more
Two years since the KeepSight launch, Insight asks what measurable difference this once-in-a-generation program is making to those living with the diabetes.